Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
A linear type of several low molecular weight CXCR4 antagonists were developed based on T140 analogs, which were previously found to be strong CXCR4 antagonists that block X4-HIV-1 entry and have inhibitory activities against cancer metastasis/progression and rheumatoid arthritis.
Tamamura
Hirokazu
H
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Japan. tamamura.mr@tmd.ac.jp
Tsutsumi
Hiroshi
H
Masuno
Hiroyuki
H
Mizokami
Satoko
S
Hiramatsu
Kenichi
K
Wang
Zixuan
Z
Trent
John O
JO
Nakashima
Hideki
H
Yamamoto
Naoki
N
Peiper
Stephen C
SC
Fujii
Nobutaka
N
D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D002460:Cell Line; D006801:Humans; D008970:Molecular Weight; D009842:Oligopeptides / Q000737:chemistry* / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*
D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D009842:Oligopeptides; D010456:Peptides, Cyclic; D019718:Receptors, CXCR4; C116977:T140 peptide